Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says

Drugmakers have delayed the launches of some medicines in Europe as the industry deals with U.S. pressure and pricing shifts from President Donald Trump, Maggie Fick, Bhanvi Satija and Dominique Patton of Reuters reports, citing executives, pricing policy shifts, and data shared with the journal. The White House has been pushing for lower prescription drug costs, with Trump looking to tie the cost for Americans to what is paid elsewhere. This has led drugmakers to pause bringing some medicines to European markets to avoid pulling down prices in the U.S. market. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).